Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.42 |
| ▸ | MMP9 | P14780 | 5/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093775 | 0.89 | MMP2 (0.43) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL3092417 | 0.86 | MMP2 (0.39) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL3084192 | 0.81 | CNR1 (0.36) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL5482223 | 0.76 | CNR1 (0.61) | MMP2MMP9CNR1HTTGPR35 | |
| SCHEMBL3200621 | 0.73 | CNR1 (0.57) | MMP2MMP9CNR1HTTGPR35 | |
| SCHEMBL31003728 | 0.70 | CNR1 (0.36) | MMP2MMP9CNR1HTTGPR35 | |
| SCHEMBL3087572 | 0.68 | CNR1 (0.37) | MMP2MMP9CNR1HTTGPR35 | |
| SCHEMBL31003823 | 0.68 | CNR1 (0.37) | MMP2MMP9CNR1HTTGPR35 | |
| SCHEMBL31003782 | 0.67 | CNR1 (0.36) | MMP2MMP9CNR1HTTGPR35 | |
| SCHEMBL3085010 | 0.67 | CNR1 (0.36) | MMP2MMP9CNR1HTTGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | claimed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| WO-2008129075-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS | TOPOTARGET A/S (DK) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TPH2, TPH1, HTR2C | MMP2 2138/4885MMP9 3892/4885MMP3 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.